Results 11 to 20 of about 25,216 (236)

Bispecific antibodies for viral immunotherapy [PDF]

open access: yesHuman Vaccines & Immunotherapeutics, 2017
Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies.
Elisabeth K. Nyakatura   +2 more
doaj   +3 more sources

A novel single-vector featuring bidirectional promoters for production of bispecific antibody against rabies virus [PDF]

open access: yesBMC Biotechnology
Background The World Health Organization (WHO) recommends combination therapy with two non-overlapping monoclonal antibodies (mAbs) to enhance protection in Rabies post-exposure prophylaxis (PEP).
Zhigao Zhang   +4 more
doaj   +2 more sources

Bispecific antibody therapies

open access: yesHematology, 2023
Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique   +2 more
openaire   +3 more sources

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity

open access: yesLife, 2022
B7-H3 plays an important role in tumor apoptosis, proliferation, adhesion, angiogenesis, invasion, migration, and evasion of immune surveillance. It is overexpressed in various human solid tumor tissues.
Yan Feng   +10 more
doaj   +1 more source

Production of native bispecific antibodies in rabbits. [PDF]

open access: yesPLoS ONE, 2010
BACKGROUND: A natural bispecific antibody, which can be produced by exchanging Fab arms of two IgG4 molecules, was first described in allergic patients receiving therapeutic injections with two distinct allergens.
Wei Wang, Ruihuan Xu, Jinming Li
doaj   +1 more source

Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis

open access: yesFluids and Barriers of the CNS, 2022
Background Treatment with amyloid-β (Aβ) targeting antibodies is a promising approach to remove Aβ brain pathology in Alzheimer's disease (AD) and possibly even slow down or stop progression of the disease.
Ulrika Julku   +5 more
doaj   +1 more source

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau

open access: yesFrontiers in Nuclear Medicine, 2023
IntroductionAlzheimer's disease (AD) is characterized by the misfolding and aggregation of two major proteins: amyloid-beta (Aβ) and tau. Antibody-based PET radioligands are desirable due to their high specificity and affinity; however, antibody uptake ...
Vinay Banka   +7 more
doaj   +1 more source

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

open access: yesmAbs, 2021
Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with ...
Marlena Surowka   +2 more
doaj   +1 more source

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth

open access: yesJournal for ImmunoTherapy of Cancer, 2020
Background Small cell lung cancer (SCLC) accounts for 15% of lung cancers, and the primary treatment of this malignancy is chemotherapy and radiotherapy.
Xin Chen   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy